Effect of resveratrol on cisplatin chemotherapy sensitivity of ovarian cancer cells

Abstract

Abstract:ObjectiveTo investigate the effect and mechanism of resveratrol on cisplatin chemotherapy sensitivity of human epithelial ovarian cancer SKOV3 cells. MethodsThe cultured in vitro human ovarian cancer SKOV3 cells in logarithmic growth phase were treated with resveratrol (20 μg/ml), cisplatin (40 μg/ml) and resveratrol (20 μg/ml) + cisplatin (20 μg/ml) respectively, and the blank group was set, n=10. After 48 hours, the cellular growth inhibition rate was calculated by methyl thiazolyl thiazolium (MTT), cell cycle and apoptosis rate were analyzed by flow cytometry, the expressions of Bax mRNA and Bcl2 mRNA were detected by reverse transcriptionpolymerase chain reaction (RTPCR), and the expression of cleaved Caspase3 protein was detected by Western blotting. ResultsThe cellular growth inhibition rate of SKOV3 cells in resveratrol + cisplatin group was significantly increased than that in cisplatin group ［(53.0±8.1)% vs. (37.5±6.5)%, P=0.017］, the proportion of G0G1 phase cells in resveratrol + cisplatin group was significantly higher than that in cisplatin group ［(61.2±3.4)% vs. (54.9±2.8)%, P=0.017］, the proportion of G2M phase cells in resveratrol + cisplatin group was significantly lower than that in cisplatin group ［(5.1±0.5)% vs. (8.6±0.9)%, P=0.008］, the apoptosis index in resveratrol + cisplatin group was significantly increased than that in cisplatin group ［(59.3±7.4)% vs. (43.6±6.0)%, P=0.015］, the ratio of Bax/Bcl2 in resveratrol + cisplatin group was significantly increased than that in cisplatin group (4.6±1.8 vs. 3.3±1.4, P=0.026), and the expression of cleaved Caspase3 protein in resveratrol + cisplatin group was significantly increased than that in cisplatin group (0.47±0.15 vs. 0.38±0.12, P=0.011). Compared with blank group, the G0G1 phase in cell cycle of resveratrol group was significantly increased ［(46.5±2.4)% vs. (37.8±1.9)%, P=0.023］, the expression of Bcl2 mRNA was significantly decreased ［(32.9±11.2) ×10-3 vs. (44.8±13.0)×10-3, P=0.028］, the ratio of Bax/Bcl2 was significantly increased (2.1±0.8 vs. 1.5±0.6, P=0.019), and the expression of cleaved Caspase3 protein was significantly increased (0.26±0.10 vs. 0.08±0.03, P＜0.001). ConclusionResveratrol can effectively enhance the effect on human epithelial ovarian cancer SKOV3 cells treated by cisplatin, which is perhaps related to its effects of blocking the cell cycle G0G1 and altering the expression of apoptosisrelated genes and proteins.

Key words:Ovarian neoplasms,Cisplatin,Drug therapy,Apoptosis,Resveratrol

Li Yan. Effect of resveratrol on cisplatin chemotherapy sensitivity of ovarian cancer cells[J]. Journal of International Oncology, 2018, 45(1): 5-.

References

［1］杨双祥, 黄娅芬, 王军玲, 等. 中西医结合治疗对晚期卵巢癌的生存率和免疫学等指标的影响分析［J］. 中国临床研究, 2015, 28(8): 10901091. DOI: 10.13429 /j.cnki.cjcr.08.039. ［2］ Chen B, Xue J, Meng X, et al. Resveratrol prevents hypoxiainduced arginase Ⅱ expression and proliferation of human pulmonary artery smooth muscle cells via Aktdependent signaling［J］. Am J Physiol Lung Cell Mol Physiol, 2014, 307(4): 317325. DOI: 10.1152/ajplung.00285.2013. ［3］张雪, 邢宝恒, 曹亚磊, 等. 白藜芦醇对妊娠期糖尿病大鼠肾脏组织抗氧化和抗炎的作用［J］. 中国实验方剂学杂志, 2017, 23(2): 131137. DOI: 10.13422/j.cnki.syfjx.2017020131. ［4］王玲琳, 朱妍, 朴花子. 白藜芦醇对CXCL12诱导的胃癌细胞增殖的影响［J］. 肿瘤药学, 2015, 5(2): 101105. DOI: 10.3969/j.issn.20951264.2015.020. ［5］孙海榕, 王璐瑜, 王忠鑫. 白藜芦醇苷通过抑制microRNA21表达抑制肝癌细胞增殖和迁移［J］. 中国生物化学与分子生物学报, 2015, 31(11): 12201226. DOI: 10.13865/j.cnki.cjbmb.2015.11.15. ［6］战仕花, 王苹, 尹万忠, 等. 白藜芦醇对喉癌Hep2细胞顺铂敏感性的增强作用及其机制［J］. 吉林大学学报(医学版), 2015, 41(2): 282286. DOI: 10.13481/j.1671587x.20150214. ［7］杨璐, 刘延国, 李际盛, 等. 蟾毒灵对非小细胞肺癌顺铂化疗的增敏作用及机制［J］. 山东大学学报(医学版), 2015, 53(3): 611. DOI: 10.6040/j.issn.16717554.0.2014.934. ［8］张爽爽, 夏庆民, 郑荣寿, 等. 中国2010年卵巢癌发病与死亡分析［J］. 中国肿瘤, 2016, 25(3): 169173. DOI: 10.11735/j.issn.10040242.2016.03.A003. ［9］张雯碧. 卵巢癌化疗耐药相关基因与预后的研究进展［J］. 国外医学妇产科学分册, 2007, 3(34): 193196. DOI: 10.3969/j.issn.16741870.2007.03.014. ［10］ Lee DK, Kim JS, Kwon SU, et al. Lesion patterns and stroke mechanism in atherosclerotic middle cerebral artery disease［J］. Stroke, 2005, 36(12): 25832588. DOI: 10.1161/01.STR.0000189999.19948.14. ［11］赵丹懿, 戴朝霞, 陈骏, 等. 白藜芦醇对肝癌细胞Bel7402的抑制作用及其效应机制分析［J］. 中国生化药物杂志, 2014, 34(7): 68. ［12］李向宇, 徐乐, 柳垂亮, 等. 电针对异氟醚引起的APPswe/PS1dE9小鼠学习记忆能力及海马激活型Caspase3、Bcl2/Bax变化的影响［J］. 针刺研究, 2016, 41(1): 2430. DOI: 10.13702/j.10000607.2016.01.004. ［13］ Ogura T, Tanaka Y, Tamaki H, et al. Docetaxel induces Bcl2 and proapoptosis caspaseindependent death of human prostate cancer DU145 cells［J］. Int J Oncol, 2016, 48(6): 23302338. DOI: 10.3892/ijo.2016.3482. ［14］刘郁东, 郑启新, 吴宏斌, 等. 雷帕霉素对不同肿瘤细胞Bax/Bcl2和活性caspase3表达的影响［J］. 肿瘤, 2013, 33(2): 138143. DOI: 10.3781/j.issn.1000 7431.2013.02.006. ［15］ Saeedi Borujeni MJ, Hami J, Haghir H, et al. Evaluation of Bax and Bcl2 proteins expression in the rat hippocampus due to childhood febrile seizure［J］. Iran J Child Neurol, 2016, 10(1): 5360.

[1]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[2]	Ren Lu, Xie Xiaoli, Zhang Kun, Wang Lijuan.Effects and mechanisms of dihydroartemisinin combined with carfilzomib on the activity， proliferation， and apoptosis of multiple myeloma cells[J]. Journal of International Oncology, 2024, 51(3): 129-136.
[3]	Gong Yan, Chen Honglei.Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer[J]. Journal of International Oncology, 2024, 51(3): 186-190.
[4]	Yue Hongyun, Zhang Baihong.Differentiation therapies in human cancers[J]. Journal of International Oncology, 2024, 51(2): 109-113.
[5]	Jin Xudong, Chen Zhongjian, Mao Weimin.Research progress on the role of MTAP in malignant mesothelioma[J]. Journal of International Oncology, 2024, 51(2): 99-104.
[6]	Zhang Keping, Zhao Yongsheng, Yang Juan, Fu Maoyong.Chlorogenic acid induces mitochondrial dysfunction in lung cancer A549 cells by inhibiting the PI3K-Akt pathway[J]. Journal of International Oncology, 2024, 51(1): 21-28.
[7]	Xiang Yuling, Tan Jiajie, Xiong Yuanguo, Zhao Lirong, Li Chen, Zhang Hong.Effects of Anhydroicaritin on the proliferation， migration and apoptosis of hepatocellular carcinoma cells[J]. Journal of International Oncology, 2023, 50(9): 513-519.
[8]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng.Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway[J]. Journal of International Oncology, 2023, 50(8): 449-456.
[9]	An Rong, Liu Meihua, Wang Peichen, Wang Xiaohui.Research progress of Nrf2 in ovarian cancer[J]. Journal of International Oncology, 2023, 50(8): 493-497.
[10]	Zhang Jinnan, Liu Bangqing, Li Jun, Liu Xiaohui.Research on BHLHE40 targets HMGA2 to reduce the sensitivity of thyroid cancer cells to cisplatin through activating the oxidative phosphorylation pathway[J]. Journal of International Oncology, 2023, 50(7): 398-406.
[11]	Wu Jiali, Zhang Jiahui, Zhang Ping, Xiao Xinyue, Li Rui, Zhang Hongyu.Mechanism of Bcl-2 BH4 selective inhibitor BDA-366 on NK/T cell lymphoma cells[J]. Journal of International Oncology, 2023, 50(7): 413-418.
[12]	Li Chenxi, Zhao Hongwei.Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery[J]. Journal of International Oncology, 2023, 50(6): 342-347.
[13]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367.
[14]	Yang Ya, Wang Huili, Liu Yan, Guo Jinfeng, Wang Chunxia, Lyu Min, Shan Changping.Effects of GCSH gene on proliferation and apoptosis of gastric cancer SNU-1 cells[J]. Journal of International Oncology, 2023, 50(5): 257-262.
[15]	Yang Lirong, Wang Yufeng.Construction of machine learning models for predicting the risk of postoperative distant metastasis recurrence in serous ovarian cancer[J]. Journal of International Oncology, 2023, 50(4): 220-226.